JP2005528367A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005528367A5 JP2005528367A5 JP2003579815A JP2003579815A JP2005528367A5 JP 2005528367 A5 JP2005528367 A5 JP 2005528367A5 JP 2003579815 A JP2003579815 A JP 2003579815A JP 2003579815 A JP2003579815 A JP 2003579815A JP 2005528367 A5 JP2005528367 A5 JP 2005528367A5
- Authority
- JP
- Japan
- Prior art keywords
- group
- formula
- optionally
- alkyl
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 150000001875 compounds Chemical class 0.000 claims description 35
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 7
- QMNUDYFKZYBWQX-UHFFFAOYSA-N 3H-quinazolinyl-4-one Natural products C1=CC=C2C(=O)N=CNC2=C1 QMNUDYFKZYBWQX-UHFFFAOYSA-N 0.000 claims description 4
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 claims description 4
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 claims description 4
- 125000004603 benzisoxazolyl group Chemical group O1N=C(C2=C1C=CC=C2)* 0.000 claims description 2
- -1 benzo [1,3] dioxolyl Chemical group 0.000 claims description 2
- 125000001041 indolyl group Chemical group 0.000 claims description 2
- 125000000842 isoxazolyl group Chemical group 0.000 claims description 2
- 125000004592 phthalazinyl group Chemical group C1(=NN=CC2=CC=CC=C12)* 0.000 claims description 2
- 125000003373 pyrazinyl group Chemical group 0.000 claims description 2
- 125000003226 pyrazolyl group Chemical group 0.000 claims description 2
- 125000004076 pyridyl group Chemical group 0.000 claims description 2
- 125000005493 quinolyl group Chemical group 0.000 claims description 2
- 125000001544 thienyl group Chemical group 0.000 claims description 2
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 27
- 125000003118 aryl group Chemical group 0.000 claims 16
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 15
- 125000004890 (C1-C6) alkylamino group Chemical group 0.000 claims 13
- 239000002253 acid Substances 0.000 claims 13
- 125000000753 cycloalkyl group Chemical group 0.000 claims 12
- 150000003839 salts Chemical class 0.000 claims 11
- 125000001072 heteroaryl group Chemical group 0.000 claims 10
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 10
- 125000003831 tetrazolyl group Chemical group 0.000 claims 10
- 229910052736 halogen Inorganic materials 0.000 claims 9
- 150000002367 halogens Chemical class 0.000 claims 9
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims 9
- 150000001204 N-oxides Chemical class 0.000 claims 8
- 125000003282 alkyl amino group Chemical group 0.000 claims 8
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims 7
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 7
- 125000003161 (C1-C6) alkylene group Chemical group 0.000 claims 6
- 125000004093 cyano group Chemical group *C#N 0.000 claims 6
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims 5
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 5
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 5
- 201000010099 disease Diseases 0.000 claims 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 5
- 125000004043 oxo group Chemical group O=* 0.000 claims 5
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical group N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 4
- 125000004432 carbon atom Chemical group C* 0.000 claims 4
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 125000002619 bicyclic group Chemical group 0.000 claims 3
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 3
- 208000030507 AIDS Diseases 0.000 claims 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims 2
- 150000007513 acids Chemical class 0.000 claims 2
- 239000004480 active ingredient Substances 0.000 claims 2
- 125000000217 alkyl group Chemical group 0.000 claims 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 2
- 238000010438 heat treatment Methods 0.000 claims 2
- 125000005842 heteroatom Chemical group 0.000 claims 2
- 239000012442 inert solvent Substances 0.000 claims 2
- 229910052757 nitrogen Chemical group 0.000 claims 2
- 229910052760 oxygen Inorganic materials 0.000 claims 2
- 239000001301 oxygen Substances 0.000 claims 2
- 125000003367 polycyclic group Chemical group 0.000 claims 2
- 229910052717 sulfur Inorganic materials 0.000 claims 2
- 239000011593 sulfur Chemical group 0.000 claims 2
- UMGDCJDMYOKAJW-UHFFFAOYSA-N thiourea Chemical compound NC(N)=S UMGDCJDMYOKAJW-UHFFFAOYSA-N 0.000 claims 2
- LWVOMFANLNNCBU-UHFFFAOYSA-N 2,3,5-trichloro-6-(3-phenyl-2-phenylimino-1,3-thiazol-5-yl)benzene-1,4-diol Chemical compound OC1=C(Cl)C(Cl)=C(O)C(C=2SC(=NC=3C=CC=CC=3)N(C=3C=CC=CC=3)C=2)=C1Cl LWVOMFANLNNCBU-UHFFFAOYSA-N 0.000 claims 1
- FCESHAYLBHWJRQ-UHFFFAOYSA-N 2,3,5-trichloro-6-(3-phenyl-2-phenylimino-1,3-thiazol-5-yl)cyclohexa-2,5-diene-1,4-dione Chemical compound O=C1C(Cl)=C(Cl)C(=O)C(C=2SC(=NC=3C=CC=CC=3)N(C=3C=CC=CC=3)C=2)=C1Cl FCESHAYLBHWJRQ-UHFFFAOYSA-N 0.000 claims 1
- CVVOSKXDSAEQBG-UHFFFAOYSA-N 3-cyclohexyl-n,5-diphenyl-1,3-thiazol-2-imine Chemical compound C1CCCCC1N(C=C(S1)C=2C=CC=CC=2)C1=NC1=CC=CC=C1 CVVOSKXDSAEQBG-UHFFFAOYSA-N 0.000 claims 1
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims 1
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims 1
- ZNWKOOJMYXBJED-PYCFMQQDSA-N CN1C=C(C=2C=C3N=CN=C(N)C3=CC=2)S\C1=N/C1CCCC(O)C1 Chemical compound CN1C=C(C=2C=C3N=CN=C(N)C3=CC=2)S\C1=N/C1CCCC(O)C1 ZNWKOOJMYXBJED-PYCFMQQDSA-N 0.000 claims 1
- IDFPQOJFKIXOBS-PYCFMQQDSA-N CN1C=C(C=2C=C3N=CN=C(N)C3=CC=2)S\C1=N/C1CCCCC1 Chemical compound CN1C=C(C=2C=C3N=CN=C(N)C3=CC=2)S\C1=N/C1CCCCC1 IDFPQOJFKIXOBS-PYCFMQQDSA-N 0.000 claims 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 1
- 208000018522 Gastrointestinal disease Diseases 0.000 claims 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 208000001132 Osteoporosis Diseases 0.000 claims 1
- 208000016222 Pancreatic disease Diseases 0.000 claims 1
- 229940123304 Phosphodiesterase 7 inhibitor Drugs 0.000 claims 1
- 206010039085 Rhinitis allergic Diseases 0.000 claims 1
- 210000001744 T-lymphocyte Anatomy 0.000 claims 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Natural products NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims 1
- 208000026935 allergic disease Diseases 0.000 claims 1
- 201000010105 allergic rhinitis Diseases 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 208000015114 central nervous system disease Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000002124 endocrine Effects 0.000 claims 1
- 230000004720 fertilization Effects 0.000 claims 1
- 125000005843 halogen group Chemical group 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 125000002950 monocyclic group Chemical group 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 201000008482 osteoarthritis Diseases 0.000 claims 1
- 208000024691 pancreas disease Diseases 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 239000002606 phosphodiesterase VII inhibitor Substances 0.000 claims 1
- 238000000746 purification Methods 0.000 claims 1
- 208000023504 respiratory system disease Diseases 0.000 claims 1
- 229920006395 saturated elastomer Polymers 0.000 claims 1
- 238000000926 separation method Methods 0.000 claims 1
- 239000007858 starting material Substances 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
- 238000002054 transplantation Methods 0.000 claims 1
- 208000009935 visceral pain Diseases 0.000 claims 1
- 0 *[*@](C=C(*)S1)C1=N* Chemical compound *[*@](C=C(*)S1)C1=N* 0.000 description 2
- 125000001424 substituent group Chemical group 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP02290787A EP1348433A1 (en) | 2002-03-28 | 2002-03-28 | Thiazol-2-yl-imine compounds as PDE-7 inhibitors |
| PCT/EP2003/002276 WO2003082277A1 (en) | 2002-03-28 | 2003-03-06 | Thiazol-2-yl-imine compounds as pde-7 inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2005528367A JP2005528367A (ja) | 2005-09-22 |
| JP2005528367A5 true JP2005528367A5 (enExample) | 2006-04-20 |
Family
ID=27798933
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003579815A Abandoned JP2005528367A (ja) | 2002-03-28 | 2003-03-06 | Ｐｄｅ−７阻害剤としてのチアゾール−２−イル−イミン化合物 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US6852720B2 (enExample) |
| EP (2) | EP1348433A1 (enExample) |
| JP (1) | JP2005528367A (enExample) |
| AU (1) | AU2003215635A1 (enExample) |
| BR (1) | BR0308807A (enExample) |
| CA (1) | CA2480568A1 (enExample) |
| MX (1) | MXPA04009421A (enExample) |
| WO (1) | WO2003082277A1 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2554696C (en) | 2004-02-13 | 2009-06-30 | Warner-Lambert Company Llc | Androgen receptor modulators |
| EP1737813A1 (en) | 2004-04-13 | 2007-01-03 | Warner-Lambert Company LLC | Androgen modulators |
| WO2005102990A1 (en) | 2004-04-22 | 2005-11-03 | Warner-Lambert Company Llc | Androgen modulators |
| US8012971B2 (en) | 2005-04-28 | 2011-09-06 | Dainippon Sumitomo Pharma Co., Ltd. | Therapeutic agent for chronic obstructive pulmonary disease |
| TW200724139A (en) | 2005-05-05 | 2007-07-01 | Warner Lambert Co | Androgen modulators |
| ZA200804550B (en) | 2005-11-09 | 2009-08-26 | Combinatorx Inc | Methods, compositions, and kits for the treatment of medical conditions |
| WO2008119057A2 (en) * | 2007-03-27 | 2008-10-02 | Omeros Corporation | The use of pde7 inhibitors for the treatment of movement disorders |
| US8637528B2 (en) | 2007-03-27 | 2014-01-28 | Omeros Corporation | Use of PDE7 inhibitors for the treatment of movement disorders |
| US9220715B2 (en) | 2010-11-08 | 2015-12-29 | Omeros Corporation | Treatment of addiction and impulse-control disorders using PDE7 inhibitors |
| KR20130124333A (ko) | 2010-11-08 | 2013-11-13 | 오메로스 코포레이션 | Pde7 억제제를 사용한 중독 및 충동-조절 장애의 치료 |
| AU2023326563A1 (en) | 2022-08-18 | 2025-02-27 | Mitodicure Gmbh | Use of a therapeutic agent with phosphodiesterase-7 inhibitory activity for the treatment and prevention of diseases associated with chronic fatigue, exhaustion and/or exertional intolerance |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2203086T3 (es) * | 1998-02-17 | 2004-04-01 | Roche Diagnostics Gmbh | Empleo de derivados de tiadiazolo (4,3-a)piridina. |
| CN100369903C (zh) * | 2000-06-30 | 2008-02-20 | 大日本住友制药株式会社 | 五元环化合物 |
-
2002
- 2002-03-28 EP EP02290787A patent/EP1348433A1/en not_active Withdrawn
-
2003
- 2003-03-06 MX MXPA04009421A patent/MXPA04009421A/es active IP Right Grant
- 2003-03-06 CA CA002480568A patent/CA2480568A1/en not_active Abandoned
- 2003-03-06 WO PCT/EP2003/002276 patent/WO2003082277A1/en not_active Ceased
- 2003-03-06 JP JP2003579815A patent/JP2005528367A/ja not_active Abandoned
- 2003-03-06 BR BR0308807-3A patent/BR0308807A/pt not_active IP Right Cessation
- 2003-03-06 AU AU2003215635A patent/AU2003215635A1/en not_active Abandoned
- 2003-03-06 EP EP03745261A patent/EP1492530A1/en not_active Withdrawn
- 2003-03-27 US US10/402,235 patent/US6852720B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3209656B1 (en) | Indole carboxamides compounds useful as kinase inhibitors | |
| JP2022506887A5 (enExample) | ||
| CA2785923C (en) | Therapeutic compounds and related methods of use | |
| ES2309443T3 (es) | 2-(2,6-dioxopiperidin-3-il)-ftalimidas sustituidas y metodo para reducir los niveles de tnf alfa. | |
| JP2008513516A5 (enExample) | ||
| AU2015335783B2 (en) | Tricyclic atropisomer compounds | |
| KR102345381B1 (ko) | 키나제 억제제로서 유용한 카르바졸 카르복스아미드 화합물 | |
| JP2018505898A5 (enExample) | ||
| JP2008513496A5 (enExample) | ||
| JP2006507355A5 (enExample) | ||
| CA2753135A1 (fr) | Derives de pyrazolo[1,5-.alpha.]-1,3,5-triazines, leur preparation et leur application en therapeutique | |
| ZA200508158B (en) | Derivatives of piperidinyl- and piperazinyl-alkyl carbamates, preparation methods thereof and application of same in therapeutics | |
| FR2806086A1 (fr) | Base cristalline du citalopram | |
| KR102242265B1 (ko) | 비시클릭 화합물 | |
| JP2005539045A5 (enExample) | ||
| JP2000505451A (ja) | キノロン類およびこれらの治療的使用 | |
| HUP9903797A2 (hu) | Benzofurán-karboxamidok és -szulfonamidok, alkalmazásuk gyógyszerkészítmények előállítására és ezek a gyógyszerkészítmények | |
| WO2011107709A1 (fr) | Utilisation d'isoquinolones pour la preparation de medicaments, nouvelles isoquinolones et leur procede de synthese | |
| JP2005531526A (ja) | Ｐｄｅ７阻害剤としての（４，２−２置換−チアゾール−５−イル）アミン化合物 | |
| JP2004525183A5 (enExample) | ||
| JP2018522915A5 (enExample) | ||
| CN101525316A (zh) | 喹啉类衍生物及其制备方法和用途 | |
| JP2005528367A (ja) | Ｐｄｅ−７阻害剤としてのチアゾール−２−イル−イミン化合物 | |
| RU2006103790A (ru) | Производные такрина в качестве ингибиторов ацетилхолинэстеразы | |
| FR3050732B1 (fr) | Nouveaux derives de phosphinolactones et leurs utilisations pharmaceutiques |